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Abstract (224) 
Hereditary spherocytosis originates from defective anchoring of the cytoskeletal network to the 
transmembrane protein complexes of the red blood cell. Red cells in hereditary spherocytosis are 
characterized by membrane instability, reduced deformability and a large heterogeneity in 
disease severity among patients. To unravel this variability in disease severity, we analyzed blood 
samples from 21 spherocytosis patients with defects in ankyrin, band 3, α-spectrin and β-spectrin 
using red cell indices, eosin-5-maleimide binding, microscopy and the osmotic fragility test, 
Percoll density gradients, vesiculation and ektacytometry to assess cell membrane stability, 
cellular density and deformability. Reticulocyte counts, CD71 abundance, band 4.1 a:b ratio, and 
HbA1c were used as markers of red blood cell turnover. We observed that patients with 
moderate/severe spherocytosis have short-living erythrocytes of low density and abnormally 
high intercellular heterogeneity. These cells show a prominent decrease in membrane stability 
and red cell deformability and, as a consequence, are quickly removed from the circulation by 
the spleen. In contrast, in mild spherocytosis less pronounced reduction in deformability results 
in prolonged red cell life-span and, hence, cells are subject to progressive loss of membrane. Red 
blood cells from patients with mild spherocytosis thus become denser before they are taken up 
by the spleen. Based on our findings, we conclude that red blood cell membrane loss, cellular 
heterogeneity and density are strong markers of clinical severity in spherocytosis.  
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Abbreviations 
CDPA = citrate phosphate dextrose adenine 
EI
max
 = maximal elongation index 
EMA = eosin-5′-maleimide 
MCHC = mean corpuscular hemoglobin concentration 
MCV = mean corpuscular volume 
MPA = mean projected area 
MPA DW = mean projected area distribution width 
OFT = osmotic fragility test 
O
min 
= hypotonic osmolarity where EI is minimal 
O
hyper
 = hypertonic osmolarity at 50% of EI
max
 
RBCs = red blood cell 
RBCVs = red blood cell-derived vesicles 
RDW = red blood cell distribution width  
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Introduction 
Hereditary spherocytosis (HS) is the most common form of chronic hereditary hemolytic anemia 
in the Caucasian population, with an estimated prevalence of 1:2000 – 1:5000
1–3
. HS usually 
originates from mutations in ANK1 (ankyrin), SLC4A1 (band 3), SPTA1 (α-spectrin), SPTB (β-
spectrin) or EPB42 (protein 4.2)
1
. Anemia in HS may require transfusion(s) and in severe cases 
splenectomy. A characteristic feature of HS is red blood cell (RBC) membrane instability, which 
leads to membrane loss and formation of dense cells with reduced RBC deformability
4–6
. 
Increased RBC density is an important feature of HS
7
 and is, for example, reflected by increased 
mean corpuscular hemoglobin concentrations (MCHC)
8,9
.  
HS is a very heterogeneous RBC disorder, resulting from a wide range of molecular defects and 
characterized by a high degree of heterogeneity in RBC properties and disease severity
8–12
. In 
fact, even for HS patients with identical mutations, considerable differences in disease-severity 
are reported. It therefore seems reasonable to assume that the heterogeneity in disease severity 
is not only a reflection of particular genotype but is also impacted by other factors that control 
RBC properties. 
Healthy RBCs become increasingly dense during their lifespan
13,14
, but this process is accelerated 
in HS
1
. Shedding of essentially hemoglobin-free vesicles results in an increase in MCHC and a 
corresponding increase in RBC density and intracellular viscosity
13,15
. Electrogenic potassium leak 
also contributes to RBC dehydration in HS patients and is not compensated by Na
+
 
accumulation
16,17
. As a result, intracellular K
+
 concentration in RBCs of patients ≈ 13 mmol/L 
lower than in cells of healthy subjects
16
, which results in net ion and water loss. Compensatory 
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activation of Na,K-ATPase in RBCs of patients was insufficient to prevent the loss of K
+
 and 
dissipation of K
+
/Na
+
 gradients. Function of other electroneutral ion transporters (KCC, NKCC, 
Na/Li exchanger) in RBCs of HS patients was reported to be indistinguishable from that of cells 
of healthy controls
16,18
. 
In this study, we investigated a unique and genetically well-diagnosed group of HS patients on 
which we performed an in-depth analysis of RBC properties in HS, such as membrane instability, 
cellular density, cellular heterogeneity, vesiculation, turnover and lifespan. The obtained data 
were then correlated to clinical manifestations of HS, in both non-splenectomized and 
splenectomized patients, in order to identify markers of disease severity. Our results indicate that 
clinical severity in HS cannot be solely attributed to the protein harboring the mutation, but 
rather to the stability of the whole cytoskeletal network. RBC density, heterogeneity and 
deformability were identified as potential markers of severity. We found that the presence of 
dense RBCs is strongly associated with a milder HS manifestation. We hypothesize that unstable 
RBCs from clinically more severe patients are removed from the circulation before they acquire 
the features of senescence.  
 7
Methods  
Subjects 
Patients previously diagnosed with HS were enrolled in the CoMMiTMenT-study 
(http://www.rare-anaemia.eu/). This study was approved by the Medical Ethical Research Board 
of the University Medical Center Utrecht, the Netherlands, under reference code 15/426M and by 
the Ethical Committee of Clinical Investigations of Hospital Clinic, Spain, (IDIBAPS) under 
reference code 2013/8436.  
 
Hemocytometry analysis 
Hemocytometry parameters were analyzed on the Abbott Sapphire cell analyzer (Abbott 
Diagnostics Division, Santa Clara, CA, USA) and ADVIA 2120 (Hematology System, Siemens 
Healthcare Diagnostics, Forchheim, Germany) 
Capillary-based measurements of MCV and MCHC 
Triplicates of heparinized blood samples were filled in capillaries and centrifuged for 5 min at 
12.000 rpm (Hematocrit 20, Hettich Zentrifugen). MCV was calculated using the formula; MCV = 
hematocrit / [RBC number] and MCHC was calculated using the formula; MCHC = [Hemoglobin] 
/ hematocrit.  
Separation on the Percoll density gradient and determination of intracellular potassium levels 
Intact blood samples were layered over a 90% isotonic Percoll solution containing plasma-like 
components as described elsewhere
19
. Briefly, Percoll density gradient and RBC separation were 
performed during the centrifugation at 50.000g for 15 min. (Sorvall RC 5C plus, rotor SM-24). 
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Intracellular potassium was measured using the Instrumentation Laboratory IL943 Flame 
Photometer according to Jokinen et al.
20 
 
Osmotic gradient ektacytometry, osmotic fragility test (OFT) and EMA-binding 
Osmotic gradient ektacytometry measurements of RBCs from healthy controls and HS patients 
were obtained using the Osmoscan module on the Lorrca MaxSis (Mechatronics, The Zwaag, The 
Netherlands) as previously described
5,21
.  The OFT was carried out as previously described by 
Parpart et al.
22 
and the eosin-5-maleimide (EMA) binding was determined according to 
previously published protocols
12,23
. 
 
RBC production, heterogeneity, vesiculation and turnover rate markers  
RBCs were stained with anti-CD71 and isotype controls and were subsequently measured using a 
BD FACS Gallios
24
. HbA1c measurements is an established tool to acquire information about RBC 
clearance and RBC age in hemolytic anemia-research
15,25
. HbA1c levels were measured using the 
Menarini/ARKRAY HA-8180V. Band 4.1a:b ratio was detected in RBC membrane lysates after 
protein separation on the inverse SDS-PAGE gel (15-7.5%) and visualization of protein bands 
using Coomassie blue staining.  Microscopic evaluation of RBC projected area and its 
heterogeneity was performed as described elsewhere
26,27
. RBC vesicles were measured from 
CDPA plasma
19
 by staining them with mouse anti-human CD235a-APC and measure them using 
the Beckman Coulter CytoFLEX flow cytometer (S.Fig 1).  
 
Statistical analysis and phenotype correlations 
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One-Way ANOVA with Post Hoc correction (Tukey) was used to compare sample means and 
Fisher’s Exact Test was used to test whether clinical severity was proportionally distributed along 
the different genotypes. In non-splenectomized patients, clinical severity was assessed based on 
1) hemoglobin and 2) reticulocytes levels which was previously defined by Bolton-Maggs et al.
11
 
(i.e. mild and moderate/severe). To prevent any confounders by splenectomized patients 
(designated as red dots), phenotype correlations were only carried out for unsplenectomized HS 
patients. Significant differences are depicted with horizontal bars, and significance levels are 
noted with * (P≤0.05), † (P≤0.01) or ‡ (P≤0.001). 
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Results 
Baseline characteristics and red cell features of HS patients 
Twenty-one patients with HS were included in this study and categorized according to clinical 
severity (Table 1)
11
. HS was confirmed by targeted NGS of the seven genes most commonly 
mutated in HS (van Vuren et al., in press). Splenectomy or a moderate/severe expression of 
disease was statistically overrepresented in patients with mutations in ANK1 and SPTB (P<0.05). 
Therefore, the phenotypic expression of HS due to ANK1 and SPTB mutations appears to be 
more severe than HS due to SLC4A1 and/or SPTA1 defects. Decreased EMA staining, reflecting 
band 3 protein loss, was seen in all patients. Patients with SPTA1 mutations tended to have 
higher EMA staining (Fig 1a), although the number of patients is too low to draw firm 
conclusions. The maximal deformability of RBCs, reflected by a decrease in EI
max
 as determined 
by the osmoscan, was decreased in all HS patients compared to healthy controls. This decrease 
was more pronounced in patients with ANK1 and SPTB mutations compared to patients with 
mutations in SPTA or SCL4A1 (Fig 1b). On the other hand, cells from patients with SLC4A1 
mutations tended to be more dehydrated as the O
hyper
 value was lower compared with both 
control blood samples and patients with SPTA1 mutations (Fig 1c). The latter patients also 
showed the least pronounced loss of surface area-to-volume ratio, reflected by a normal O
min
 
(Fig 1d) on the Osmoscan and normal results from the osmotic fragility test (50% lysis point) (Fig 
1e).  Membrane stability was compromised in all other HS patients. 
As expected, RBC turnover was increased in all patients: reticulocyte counts were high (Table 1) 
and aging marker band 4.1a:b ratio was below that from healthy controls in all patients (Table 1).  
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The heterogeneity of the RBCs, reflected by the red blood cell distribution width (RDW), was 
increased compared to healthy controls (Fig 1f) as was the MCHC (Fig 1g). Intracellular K
+
 
content was reduced in all patients but tended to be higher in HS patients with SPTA1 mutations 
(Fig 1h). 
An increase in heterogeneity in cell projected areas (MPA DW, Fig 2a) and a decrease in absolute 
mean values in projected area (MPA, Fig 2b) was seen in all HS patients compared to controls. 
Patients with SLC4A1 and SPTA1 mutations had cellular projected areas more similar to the 
healthy control group (Fig 2a,b). Patients with HS presented with higher heterogeneity in cell 
density compared with healthy subjects, showing more sub-fractions of M fraction and a broader 
distribution width of the M fraction (Fig 2c-e). These changes were more pronounced in patients 
with mutations in ANK1 and SPTA1. Furthermore, the M fraction of patients with SLC4A1 
mutations was lower than the cells of healthy controls, compared to the other HS patients (Fig 2f, 
S.Fig 2).  
In summary, specific changes were observed in parameters associated with membrane stability, 
stiffness and deformability, as well as RBC heterogeneity of RBCs in our cohort of HS patients.  
RBC markers of severity of HS  
As described in Table 1, severity of HS in non-splenectomized patients was determined based on 
the decrease in hemoglobin levels and increase in reticulocyte counts
11
. In our patients Hb levels 
positively correlated with MCHC levels (Fig 3a). An inverse correlation was observed between Hb 
and RDW (Fig 3b), and Hb and reticulocyte counts (Fig 3c). Furthermore, an inverse correlation 
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was observed between Hb and parameters defining RBC hydration status such as intracellular K
+
 
or O
hyper
 (Fig d, e).  
Decreases in RBC life-span was assessed by a reduction in changes in HbA1c in severe 
nonsplectomized HS patients, whereas in patients with mild disease manifestation or in 
splenectomized patients HbA1c levels were within the normal range (Fig 4a).  
Patients with moderate/severe HS had less deformable RBCs reflected by lower El
max
 values than 
patients with mild HS or splenectomized patients (Fig 4b). Red blood cells of mild HS patients 
also tended to be more dehydrated based on the O
hyper
 measurements (Fig 4c). In line with this, 
patients with mild HS showed higher MCHC values than moderate/severely affected patients (Fig 
4d) and had higher density of M fraction based on its position within the Percoll gradient (Fig 4e, 
S.Fig 2).  
Membrane loss was more pronounced in patients with moderate/severe HS based on reduced 
MPA (Fig 4f). In line with this, the number of RBCVs detected in plasma of moderate-severe HS 
patients was higher than in patients with mild HS (Fig 4g). No difference in EMA staining was 
however observed between mild and moderate/severe HS (Fig 4c). Inter-cellular heterogeneity 
(RDW and MPA DW) was increased in moderate-severe HS patients compared with mild HS 
patients and healthy controls (Fig 4i, j).  
In summary, patients with more severe expression of the disease had red cells with reduced life 
span and less stable membrane. Cells were smaller and more heterogeneous in size and density. 
Strikingly, patients with mild HS had red blood cells that were more dense and had higher MCHC 
values (Fig 4d, e).  
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Effect of splenectomy on RBC markers of severity  
Splenectomy performed in moderate-severe HS patients results in an increase in Hb levels and 
erythrocyte counts (data not shown). In our cohort it also is associated with a decrease in RDW 
(Fig 5a, and normalization of RBC morphology (S.Fig 3, S.Fig 4)).  Survival of RBCs from 
splenectomized HS patients, as assessed by HbA1c content or band 4.1a:b ratio, was found to be 
increased (Fig 5b, 5c). 
Several parameters remained unaffected by splenectomy. Splenectomy did not alter MCHC (Fig 
d) or intracellular K
+
 levels (Fig 5e) and did not correct band 3 loss (Fig 5f). It also did not affect 
deformability (no effect on El
max
 and O
hyper
) (Fig 5g,h). However, the cells did survive for longer 
time in the circulation despite an increase in osmotic fragility (Fig 5i).  
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Discussion 
 
This comprehensive study on a well-characterized cohort of patients offers insight into the 
variable phenotypic manifestations of HS, possible causes of clinical heterogeneity, and severity 
or the impact of splenectomy. We show here that strong markers of moderate/severe expression 
of HS are (1) lower RBC density, reflected by differences in MCHC and fractionation of RBCs on 
the Percoll density gradient, (2) reduced RBC deformability and increased membrane loss as 
determined by RBC vesicle numbers and a decrease in MPA, and (3) heterogeneity in RBC 
population reflected by differences in RDW and fractionation of RBCs using a Percoll gradient. 
We conclude that patients with moderate/severe HS have short-lived RBCs of lower density and 
abnormally high intercellular heterogeneity, whereas in mild HS less pronounced reduction in 
deformability results in prolonged RBC life-span and, hence, cells are exposed to progressive loss 
of membrane. RBCs from patients with mild HS thus become more dense before they are taken 
up by the spleen. 
 
Genotype to phenotype correlations in HS 
While previous studies were limited to protein analysis by SDS-page
12
, we used Next-Generation 
Sequencing to establish the cause of HS. This enabled us to clearly establish the primary genetic 
defect, in contrast to other conventional techniques like SDS-page which may lead to 
confounding results as it may be influenced by secondary protein defects in HS. Regardless of 
the underlying mutation all patients shared common features like increases in reticulocyte 
counts and MCHC, dehydration and an increase in RBC density, increased heterogeneity and 
overall reduction in deformability due to the destabilitsation of cytoskeletal structure
1,28
. We also 
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observed that red cell size, intracellular K
+
 content and reticulocyte counts did not differ between 
patients with SLC4A1, ANK1, SPTB and SPTA1 mutations (Fig 1h, Fig 2b, Table 1). Within one 
group of patients with the same protein mutated we noted marked differences in severity and 
clinical manifestation of the disease, the ANK1 group being the most diverse of all. We also 
noted that patients with SPTA1 mutations had a less severe phenotype (i.e. based on Hb levels, 
reticulocyte count, RDW, intracellular K
+
, and EMA staining) compared to the other patients. This 
is in contrast with the more severe disease phenotype of SPTA1 mutations reported in other 
studies
29
. Similarly, our patients with SPTB mutations presented with normal MCHC values, 
whereas in other studies MCHC was shown to be elevated in patients carrying SPTB mutations
30
. 
Due to the relatively small numbers of patients within each group we can not draw firm 
conclusions on the link between genotype and phenotypic expression.  
 
RBC density as a marker of clinical severity 
Decreased Hb, Hct and RBC counts associated with increased markers of hemolysis and 
erythropoietic activity were previously reported as markers for HS severity
9
.  Among the 
molecular mechanisms defining HS severity a major role was assigned to RBC membrane 
instability and loss of membrane proteins
28
 (MCHC, EMA test, SDS-PAGE), along with decreased 
deformability as measured by osmotic gradient ektacytometry
5
. In our cohort, increased severity 
was associated with membrane instability and extensive membrane and band 3 protein loss over 
a shorter time (Fig 4b,g-i). RBC turnover in severe HS patients was reflected by a decrease in 
HbA1c levels exceeding those in patients with mild HS (Fig 4a). The RBCs in patients with 
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moderate/severe HS had lower MCHC than those of mild HS patients (Fig 3a, 4d). The average M 
fraction density for moderate/severe HS patients RBCs did not differ from cells of healthy 
controls, whereas cells of mild HS patients showed an increase in density (Fig 4e) and lower 
deformability as they “aged”, spending more time in the circulation getting more “senescent” 
than highly unstable cells of severe HS patients. Thus, life span and decrease in El
max
 appeared to 
be a reliable marker of disease severity (Fig 4b), regardless of the genotype.  
Delayed clearance of RBCs in patients with mild HS allowed them to lose membrane more 
gradually (Fig 4g, S.Fig 3), which results in a better conservation of RBC deformability (Fig 4b) 
and the ability form dense cells (Fig 4c-e, S.Fig 2). Direct measurements of membrane shedding 
by monitoring the plasma-borne vesicles is challenging due to their fast sequestration and 
clearance
31–33
. However, higher levels of circulating RBCVs were detected in plasma from 
moderate/severe HS patients(Fig 4g). These findings are in line with an increase in other markers 
of membrane loss, such as changes in gross morphology toward spherocytic (S.Fig 3), as well as 
higher number of microcytes as detected by quantitative digital microscopy (S.Fig 4). 
RBC heterogeneity and deformability as a marker of clinical severity 
One more parameter we found to reflect disease severity in HS is RBC heterogeneity. 
Increases in RDW, RDW/Hb and MCHC/RDW ratio were suggested as HS markers for clinical 
severity
9
.  In our study RDW correlated with HS severity as well (Fig 3b). Absolute RDW values are 
known to vary between labs and depend on the age and physical activity of the subjects
34
. We 
therefore used microscopy and indeed patients with severe HS had a broader range of RBC 
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shapes and MPA DW (Fig 4 j, S.Fig 3).  
 
Word of caution for automatic detection of hematocrit and MCHC in HS patients  
MCHC was previously suggested to be prognostic for the severity of HS in non-splenectomized 
patients
9,11
. For the measurements of MCHC, we used a capillary-based method for hematocrit 
detection. In line with previous observations
35–37
 we found that automated measurements of 
MCHC of pathological RBCs are imprecise for HS patients (see S.Fig 5). Inaccuracy of automated 
MCHC detection of dehydrated RBC has been discussed for over 30 years
35
. It results from a 
substantial overestimation of MCV, both values being based on hematocrit detection or 
calculations methods
38,39
. As mentioned previously, others have shown that increased 
hemoglobin concentrations are equivalent to milder disease severity scores in HS
9,11
. We show 
that MCHC values calculated based on the capillary hematocrit correlated with blood 
hemoglobin content (Figs 1g, 3a, 4d).  
 
Conclusions  
This study reveals the factors defining RBC longevity and erythropoietic activity in patients with 
HS. These are membrane stability, which in turn depends on the localization of mutations 
impacting vertical or horizontal interactions within the membrane cytoskeleton and on the 
presence of splenic filtering capacity. Mild HS is associated with prolonged survival of RBCs in 
the circulation and allows to RBCs in mild HS to lose more membrane, which results in smaller 
and denser RBCs. Shorter-lived unstable RBCs of patients with severe HS phenotype are more 
heterogeneous and less dense, as reflected by lower MCHC. 
 18
Parameters that specifically mark clinical severity in HS are summarized in Table 2 and consist of 
RBC density (MCHC, Percoll, O
hyper
), RBC deformability (EI
max
), and RBC heterogeneity (RDW). 
They may be used to monitor the success of supportive therapy and assist in the development of 
new personalized treatment regimens.  
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Table legends 
Table 1: hemocytometry, chemistry parameters, cell-age markers and genotypes of mild, 
moderate/severe and splenectomized HS patients included in this study. Clinical severity in non-
splenectomized HS patients was assigned according to Bolton-Maggs et al.
11
 on basis of 1) 
hemoglobin and 2) reticulocytes levels. Mild HS was defined as hemoglobin levels between 110–
150 g/L, moderate HS as hemoglobin levels between 80–120 g/L and severe HS as hemoglobin 
levels lower than 80 g/L. HS patients with hemoglobin levels between 110 and 120 were 
categorized as mild or moderate on basis of their reticulocytes levels (i.e. lower or higher than 
6% reticulocytes). Novel mutations are displayed in bold face and the pathogenicity of novel 
missense variants predicted with SIFT, PolyPhen-2, and MutationTaster (results not shown). 
Notation of α
LELY
 represents SPTA1 c.[5572C>G; 6531-12C>T] p.[(Leu1858Val);(?)].   
 
Table 2: summary of parameters that characterize disease severity in HS. Symbol (↑) indicates 
increased compared to healthy controls, (↓) indicates decreased compared to healthy controls 
and (=) indicates equal to healthy controls.  
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Tables 
Table 1 
N 
 
Sex Age 
 
Genotype Hb 
(g/dL) 
 
RBC 
(10
12
/
L) 
Hct 
(%) 
MCV 
(fL) 
Ret 
(%) 
MCHC 
(g/L) 
RDW 
(%CV) 
EMA 
(%) 
O
min 
(mOsmo
l/L) 
EI
max 
(A.U.) 
O
hyper 
(mOs
mol/L
)
 
OFT 
(g/L 
NaCl) 
 
Band 
4.1/4.
2 ratio 
(A.U) 
CD71 
(%) 
Mild HS
11
 
1 
♂ 
75 ANK1 c.344T>C p.Leu115Pro  136 4,1 n.a n.a 7,2 n.a 16,2 85 162 0,555 457 7,0 0,70 0,8 
2 
♂ 
46 SLC4A1 c.1030C>T p.Arg344*   153 4,7 n.a n.a 3,2 n.a 15,2 71 163 0,563 417 6,6 0,87 1,4 
3 
♂ 
40 SLC4A1 c.1421C>A p.Ala474Asp 140 4,9 n.a n.a 4,0 n.a 12,3 93 162 0,557 427 5,7 0,99 1,2 
4 
♀ 
55 SLC4A1 c.2057+1G>A (splicing) 136 4,0 36,5 91,1 7,8 372 14,0 73 158 0,554 405 6,4 0,82 2,7 
5 
♀ 
18 SLC4A1 c.2057+1G>A (splicing) 131 3,7 35,7 96,9 9,4 367 13,1 77 166 0,569 410 6,1 0,84 1,4 
6 
♂ 
58 SLC4A1 c.2348T>A p.Ile783Asn 132 4,1 36,5 88,4 8,9 363 15,7 68 169 0,548 429 6,8 n.a 3,5 
7 
♂ 
40 SPTA1 c.678G>A p.Glu227fs + α
LELY
 127 4,1 35,9 87,8 5,8 355 15,0 94 175 0,600 453 5,6 0,84 0,9 
8 
♂ 
54 
SPTA1 c.[4339-99C>T; c.4347G>T] p.[(?; 
Lys1449Asn)]; c.4339-99C>T p.(?) 
121 3,5 34,7 98,3 3,9 348 15,3 94 160 0,566 458 5,7 n.a 0,9 
Moderate/severe HS
11
 
9 
♂ 
4 ANK 1 c.341C>T p.Pro114Leu 116 3,8 30,0 80,1 9,1 386 14,5 72 162 0,509 398 6,6 0,72 2,2 
10 
♀ 
3 ANK1 c.1943delC p.Ala648fs 117 4,02 36.3 90,4 11,9 321 21,1 59 164 0,503 424 6,6 n.a 0,2 
11 
♂ 
5 ANK1 c.2394_2397delCAGT p.Ser799fs 120 4,1 32.2 78,6 18,4 372 25,4 67 185 0,472 462 7,8 n.a 7,3 
12 
♀ 
26 ANK1 c.2559-2A>G (splicing)  102 3,3 29.4 89,5 18,3 346 24,1 84 170 0,537 446 6,4 0,60 5,3 
13 
♂ 
1 SPTB c.154delC p.Arg52fs 86 3,38 30.2 89,5 11,9 284 24,7 66 168 0,532 456 5,7 n.a 4,8 
14 
♂ 
3 SPTB c.2470C>T p.Gln824* 78 2,9 23.7 81,9 10,6 328 23,8 71 180 0,534 475 6,7 n.a 2,9 
15 
♂ 
4 SPTB c.5937+1G>A p.(?)  84 3,09 27.7 89,7 16,7 303 23,4 74 173 0,541 459 7,0 n.a 5,5 
16 
♀ 
42 SPTA1  c.2755G>T p.Glu919* + α
LELY
 113 3,5 31.7 91,8 8,2 355 16,0 89 178 0,567 471 5,9 n.a 2,1 
Splenectomized HS
11
 
17 
  31 
ANK1 c.341C>T p.Pro114Leu 152 4,9 84,7 41,9 8,4 362 11,8 76 179 0,533 437 7,4 1,08 0,1 
18 
  46 
ANK1 c.344T>C p.Leu115Pro 143 4,6 n.a. n.a. 2,8 n.a. 12,4 74 158 0,590 423 7,4 1,18 0,2 
19 
  84 
SLC4A1 c.2057+1G>A (splicing) 160 4,8 121,8 45,1 12,6 354 11,0 67 164 0,565 417 7,1 1,07 0,2 
20 
  71 
SPTB c.2136_2137delinsTT 164 4,84 100,9 48,8 2,2 337 13,2 77 173 0,509 445 7,3 0,99 0,3 
21 
  40 
SPTB c.3449G>A p.Trp1150* 163 4,94 92,0 45,5 12,2 359 11,9 73 183 0,512 440 7,8 1,22 0,3 
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Disease Severity  MCHC Density 
(Percoll, 
O
hyper
) 
RDW Reticulocytes Deformability 
(El
max
) 
Membrane 
loss 
(vesiculation) 
Mild ↑↑ ↑↑ = ↑ ↓ ↑ 
Moderate/severe ↑ ↑ ↑↑ ↑↑ ↓↓ ↑↑ 
Splenectomised ↑↑ = = ↑ = = 
Table 2 
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Figure legends 
Fig 1: basic characteristics (median ± range) of healthy controls and HS patients. HS patients 
were grouped as one group and according to their affected genes (ANK1 (ankyrin), SLC4A1 
(band 3), SPTB (β-spectrin) and SPTA1 (α-spectrin)). Blue circles represent healthy controls, black 
circles represent (unsplenectomized) HS patients and red circles represent splenectomized HS 
patients. The gray range indicates the reference range for healthy controls. Panel a) EMA-binding 
(%), b) maximum deformability (EI
max
), c) hydration state of the RBC reflected by O
hyper
, d) osmotic 
fragility measured by osmotic gradient ektacytometry and reflected in the O
min
, e) 50% lysis point 
in the osmotic fragility test, f) red blood cell distribution width (RDW) (%CV), g) MCHC by 
capillary measurements (g/L) (%CV), h) intracellular potassium (mmol/L). Significant differences 
are depicted with horizontal bars, and significance levels are noted with * (P≤0.05), † (P≤0.01) or 
‡ (P≤0.001). 
 
Fig 2: RBC heterogeneity in HS. RBC heterogeneity was measured in healthy controls and HS with 
microscopy (4a, 4b) and Percoll density gradients (4c-4f). HS patients were grouped according to 
their affected genes (ANK1 (ankyrin), SLC4A1 (band 3), SPTB (β-spectrin) and SPTA1 (α-spectrin). 
a) Mean Projected Area Distribution Width (MPA DW), b) Mean Projected Area (MPA), c) An 
example a blood sample from a patient with HS and a healthy control. On the samples the young 
RBC fraction, the main RBC fraction (fraction M) and dense RBC fractions are designated with 
green, blue and red lines. The M-fraction is subdivided in subfractions (M1, M2 etc). The position 
of the M fraction is calculated from the position of the most intense (a.u.) subfraction relative to 
the total length of Percoll column. The HS patient has 7 RBC subfractions, and the position of the 
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most intens subfraction (i.e. subfraction M3) is lower than in control (i.e. subfraction M1), d) The 
number of subfractions in the RBC density gradient, e) Fractions distribution width (%), f) 
Position of M fraction (%). Significant differences are noted by * (P≤0.05), † (P≤0.01) or ‡ 
(P≤0.001).  
 
Fig 3: RBC parameters and their relationship to clinical severity in unsplenectomized HS patients. 
a) MCHC (g/L), b) RDW (%CV), c) Reticulocytes (%), d) intracellular potassium (mmol/L), e) O
hyper
 
(mOsmol/L).  
 
Fig 4: RBC density and stability as markers of severity in HS. HS patients are grouped on clinical 
severity (i.e. mild, moderate/severe and splenectomized) (reference range in gray area). a) HbA1c 
(mmol/mol), b) maximum deformability (EI
max
), c) O
hyper
 (mOsmol/L), d) MCHC (g/L), e) Position of 
M fraction(%), f) Mean cell projected area (a.u.), g) RBC-vesicles (particles/10
12
  RBCs/L plasma), 
h) EMA-binding (%), i) RDW (%CV), j) Mean cell projected area distribution width (MPA DW). 
Significant differences are represented by horizontal bars, and significance levels are noted by * 
(P≤0.05), † (P≤0.01) or ‡ (P≤0.001).  
 
Fig 5: Role of splenectomy on RBC parameters in HS. Blue circles represent healthy controls, 
black circles represents (unsplenectomized) HS patients and red circles represent splenectomized 
HS patients. HS patients are grouped on clinical severity (i.e. mild, moderate/severe and 
splenectomized). a) RDW (%CV), b) HbA1c (mmol/mol), c) 4.1a/4.1b ratio, d) MCHC (g/L), e) 
intracellular potassium (mmol/L), f) EMA-binding hemoglobin (%), g) maximum deformability 
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(EI
max
), h) hydration state of the RBC reflected by O
hyper
 (mOsmol/L), i) 50% lysis point in the OFT 
(g/L NaCL). Significant differences are noted by * (P≤0.05), † (P≤0.01) or ‡ (P≤0.001). 
 
 





Supplemental Figures and Tables 
 
S.Fig 1: Panel a, b, c and d indicate gating strategies to detect RBC vesicles in plasma. A) Patient plasma diluted in PBS b) 
CD235a-APC diluted in PBS c) 200nm Ultra Rainbow Fluorescent Beads (Spherotech, Inc.) diluted in PBS d) 
representative APC-H vs. Violet plot of patient sample (plasma + CD235a-APC). 
 S.Fig 2: HS RBCs separated on the 90% Percoll density gradient compared to co-transported controls. Mild clinical 
severity is marked in dark-green, moderate – in pink, severe  - in orange, splenectomized – in red, controls and unaffected 
relatives marked in black. F -  father of the patient, M – mother of the patient. Control blood sample to P12 was partially 
frozen during the transportation. 
 
S.Fig 3: Representative life images of RBC resuspended in plasma-like buffer. A – cells from P19, mild anemia, B – cells 
from P7, moderate anemia, C – cells from P2, severe anemia, D – cells from splenectomized P1, E and F – cells from two 
co-transported controls.   
 
S.Fig 4: %microcytes, %normal sized RBCs and %aniocytosis in mild, moderate/severe and splenectomized HS 
measured by digital microscopy. 
 
 
 
 
 
 
 
 
 
 
 
S.Fig 5: correlations between automated and capillary measurements of hematocrit, MCV and MCHC. In blue dots 
healthy controls, black dots HS patients and red dots splenectomized HS patients dots patient are depicted. Statistical 
significant correlations are displayed with linear regression lines. a) correlations between automated hematocrit and 
capillary hematocrit measurements b) correlations between automated MCV and capillary MCV measurements, d) 
correlations between automated MCHC and capillary MCHC measurements 
 
  
Supplemental methods 
Subjects 
Patients diagnosed with HS were enrolled in the CoMMiTMenT-study (http://www.rare-anaemia.eu/) 
after spoken and written informed consent. This study was approved by the Medical Ethical Research 
Board of the University Medical Center Utrecht, the Netherlands, (UMCU) under reference code 
15/426M ‘Disturbed ion homeostasis in hereditary haemolytic anaemia’ and by the Ethical Committee of 
Clinical Investigations of Hospital Clinic, Spain, (IDIBAPS) under the reference code 2013/8436. HS 
patients were included in the study after confirming the diagnosis of HS with gold standard techniques 
(i.e. osmotic gradient ektacytometry, osmotic fragility test, EMA-binding, microscopy1) and DNA analysis 
by Next Generation Sequencing. In brief, seven genes commonly associated with RBC membrane 
disorders were analyzed: SPTA1 (a-spectrin), SPTB (b-spectrin), ANK1 (ankyrin), SLC4A1 (Band 3), EPB41 
(protein 4.1), EPB42 (protein 4.2), and RHAG (Rhesus-associated glycoprotein). After enrichment of 
genomic DNA, using a custom Agilent SureSelectXT probe kit, protein coding and flanking intronic 
sequences were determined using a SOLIDTM-5500XL system. Variants were identified using an ‘in house’ 
developed NGS mapping and calling pipeline, and the Cartagenia BENCHlab NGS module was used for 
filtering and prioritization of possible pathogenic variants. Detected mutations were confirmed by 
conventional Sanger sequencing. Novel variants with a clear pathogenic nature (i.e. frameshift mutants, 
nonsense mutants, splice site mutations) were considered to be causal. All novel missense variants were 
tested for pathogenicity using commonly known prediction tools SIFT, PolyPhen-2, and MutationTaster. 
In addition, their occurance in the healthy control population was investigated using Gnomad 
(http://gnomad.broadinstitute.org). Exclusion criteria were the use of erythrocyte transfusion in the last 
90 days, age lower than three years and body weight lower than 18kg. After inclusion, HS patients were 
categorized to their genetic defect (i.e. ANK1, SLC4A1, SPTA1 and SPTB) and to their clinical severity. 
Clinical severity in non-splenectomized HS patients was previously defined by Bolton-Maggs2 on basis of 
1) hemoglobin and 2) reticulocytes levels. Mild HS was defined as hemoglobin levels between 110–150 
g/L, moderate HS as hemoglobin levels between 80–120 g/L and severe HS as hemoglobin levels lower 
than 80 g/L. HS patients with hemoglobin levels between 110 and 120 were categorized as mild or 
moderate on basis of their reticulocytes levels (i.e. lower or higher than 6% reticulocytes). Blood from 
healthy controls was anonymously obtained using the approved medical ethical protocol of 07/125 Mini 
Donor Dienst. Patient blood was shipped with blood from a healthy control overnight from the 
University Medical Center Utrecht (Utrecht, The Netherlands) and Institut d’Investigacions Biomèdiques 
August Pi i Sunyer/ Hospital Clínic de Barcelona (Barcelona, Spain) to Saar University (Homburg, 
Germany) and University of Zurich (Zurich, Swiss) in lithium-heparin tubes either at room temperature 
or at 4C to perform advanced research tests3.  Functional domains and and protein lengths are 
obtained from Lux et al., Satchwell et al., Ding et al., Barneaud-Rocca et al., Yasunaga et al., Bennett et 
al. 4–9 and UniProt database (www.uniprot.org). 
Hemocytometry analysis 
Hemocytometry parameters (i.e. Hb, RBC numbers, hematocrit, MCV, MCH, MCHC, reticulocytes) were 
analyzed on the Abbott Sapphire cell analyzer (Abbott Diagnostics Division, Santa Clara, CA, USA) and 
ADVIA 2120 (Hematology System, Siemens Healthcare Diagnostics, Forchheim, Germany) 
Capillary-based measurements of MCV and MCHC 
Automated hematology measurements for hematocrit, MCV and MCHC can be affected various factors 
such as by shape, cell orientation and osmotic fragility10 and therefore were also measured by micro-
capillaries. Also, we used capillary-based measurements of MCV and MCHC, because RBC density 
measurements by Percoll are known to correlate with RBC age11. Hematocrit (hct) capillaries were filled 
with intact well-mixed heparinized blood samples. For each blood sample, hematocrit measurements 
were carried out in triplicate. Capillaries were centrifuged for 5 min at 12.000 rpm (Hematocrit 20, 
Hettich Zentrifugen). The total height of the samples and packed RBC height in capillary was measured 
manually with 0.1 mm accuracy. Mean hematocrit was calculated for the triplicate measurements and 
an average hematocrit was taken. MCV was calculated using the formula; MCV = hematocrit / [RBC 
number] and MCHC was calculated using the formula; MCHC = [Hemoglobin]/Hematocrit.  
 
Intracellular potassium measurements  
An aliquot lithium-heparin whole blood was directly stored at -80ºC after blood collection. At the same 
time, an aliquot of lithium heparin plasma was obtained by centrifugation of whole blood at 1000g for 
10 minutes. The obtained plasma was centrifuged again at 4000g for 10 minutes to remove debris and 
residual cells. At the day of analysis, the aliquot of whole blood underwent two additional freeze-thaw 
cycles in liquid nitrogen to ensure complete lysis. The hemolyzed whole blood and plasma samples were 
measured using the Instrumentation Laboratory IL943 Flame Photometer. Intracellular potassium 
([K+]RBC) was calculated using the following formula; 
 
 
Pre-incubated osmotic fragility test and eosin-5-maleimide binding 
For the osmotic fragility test, lithium heparinized whole blood was incubated for 24 hours at 37ºC. 
Incubated whole blood was subsequently added to different concentrations of NaCl (pH=7.4) (Range 1.0 
– 12.0 g/L). After 30 minutes of incubation, RBCs were spun down at 1250g for 5 minutes. The 
absorbance of the supernatants were measured at 540nm using a Spectramax ME2. Eosin-5-maleimide 
(EMA) binding was determined according to previously published protocols12–14. Briefly, washed RBCs 
were incubated with 0.5 mg/ml eosin-5-maleimide and measured using the BD FACSCanto®. FITC signals 
of EMA-bound RBCs from patients were percentual related to the average of EMA-signals from 6 healthy 
controls per measurement.  
 
Osmotic gradient ektacytometry  
Osmotic gradient ektacytometry measurements of RBCs from healthy controls and HS patients were 
obtained using the Osmoscan module on the Lorrca MaxSis (Mechatronics, The Zwaag, The 
Netherlands). 250µL of whole blood was standardized to a hemoglobin concentration of 12.9 g/dL and 
injected in 5ml isotonic polyvinylpyrrolidone (PVP), and osmotic gradient ektacytometry was further 
carried out as previously described15–17. Briefly, RBCs are subjected to constant shear stress (30 Pa.S) 
while the osmolarity gradually increases from ≈80 mOsmol/L to ≈550 mOsmol/L. During this increase in 
osmolarity, a refraction pattern is generated by a laser and this pattern is captured by camera. The 
accompanied software measures the elongation index (EI), which is calculated by EI=(a-b)/(a+b). In this 
formula, a represents the length and b the width of the RBC population as observed in the refraction 
pattern. Representive osmotic gradient ektacytometry curves are depicted in grey in Fig 3a-d. In the 
osmotic gradient ektacytometry curve, three characteristic points are depicted. 1) EImax represents the 
maximal deformability of the RBC population and is found whereas EI is maximal. 2) Ohyper (in mOsmol/L) 
represents the intracellular viscosity (or RBC density, or RBC hydration state) and is found at the 
hypertonic axis where the EI is 50% of EImax. Lower values of Ohyper indicate increased intracellular 
viscosity and denser RBCs. 3) Omin  (in mOsmol/L) correlates with the 50% lysis point in the manual OFT 
and is found at hypotonic conditions whereas EImin is minimal. Higher values of Omin indicates increased 
osmotic fragility (or decreased osmotic resistance).   
 
  
Separation on the Percoll density gradient 
Intact blood samples (1 ml each) were layered over the 12 ml of 90% Percoll solution containing plasma-
like components (mM) 140 NaCl, 4 KCl, 0.75 MgCl2, 2 CaCl2, 0.015 ZnCl2, 0.2 alanine, 0.2 glutamate-Na, 
0.2 glycine, 0.1 arginine, 0.6 glutamine, 10 glucose, 20 HEPES-imidazole, pH 7.40 RT, 0.1% BSA. Percoll 
density gradient and RBC separation were performed during the centrifugation at 50.000g for 15 min, no 
brakes (Sorvall RC 5C plus, rotor SM-24). To avoid RBC volume artefacts related to the cold-induced 
inhibition of Na/K pump, centrifugation was performed at 30-36ºC temperature interval.  
Tubes with the RBC separated within the Percoll density gradient were photographed in front of the 
homogeneous light source. Images were automatically analyzed by the Visio 4D software (Arivis AG) as 
follows: RBC density distribution profile within the tube was produced. From the density profile, several 
parameters describing each blood sample were determined. The density profile was divided in a fraction 
with young cells, medium cells (also defined as M fraction) and dense cells. Within the M fraction the  
number of RBC populations were counted and average RBC density was determined. The average RBC 
density was defined as the location of the most intense RBC fraction (a.u.) relative to total length of the 
Percoll gradient.  
 
RBC production, heterogeneity and turn-over rate markers  
CD71 was measured to investigate the effects of RBC turn-over and reticulocytosis on RBC density 
parameters, as CD71 is a marker of (early) reticulocytes and erythroblasts. CD71 on RBCs was measured 
using flow cytometry. Blood was resuspended in plasma-like media with pH=7.4 (in 10mM HEPES, 
120mM NaCl, 5mM KCl, 2mM CaCl2, 0.8mM MgCl2). RBCs were incubated with mouse anti-human CD71-
FITC (eBiosciences, clone OKT9). FITC IgG1 isotype control antibody was used from eBioscicences. 
Samples were measured using a BD FACS Canto II. HbA1c levels were measured in order to acquire 
information about RBC clearance18. HbA1c levels were measured using the Menarini/ARKRAY HA-8180V   
 
RBC vesicles measurements 
RBC vesicles in plasma were measured using a new generation flow cytometer, because RBC vesiculation 
is considered to increase RBC density and to cause the reduced surface-area-to-volume in HS19–21. Blood 
for RBC vesicle analysis was collected in CDPA (citrate phosphate dextrose adenine) additive solution3. 
Plasma was pipetted to new clean tubes after centrifugation for 10 minutes at 1000g. Cell debris and 
residual cells were removed from plasma after an additional centrifugation step (10 min, 4000g) and 
plasma was subsequently aliquoted and stored at -80ºC awaiting for further analysis. RBC vesicles were 
measured using the Beckman Coulter CytoFLEX flow cytometer. RBC vesicles were stained with 50µg/ml 
mouse anti-human CD235a-APC (BD Biosciences) with an equal volume of 25 times diluted CDPA plasma 
in 0.2µM filtered PBS. After incubation in the dark for 30 minutes, samples were additionally 40 times 
diluted in 0.2µM filtered PBS and measured by flow cytometry for 6 minutes with a flow speed of 
10µL/min. RBC vesicles were measured using SSC-violet-H vs. APC-H (allophycocyanin-H), and thresholds 
were set using blanks, plasma dilution samples with anti IgG2bk-APC and 200nm Ultra Rainbow 
Fluorescent Beads (Spherotech, Inc.), see S.Fig 1. Events positive for APC-H were considered to be RBC-
vesicles. RBC-vesicle concentrations were standardized to RBC numbers in blood (particles/1012 RBC/L 
plasma). 
RBC morphology evaluation with light microscopy and digital microscopy 
1,5 – 2 µl of intact blood was resuspended in 1 ml of plasma-like buffer containing 0.1% of bovine serum 
albumin. Then cell suspension was pipeted inside the microscopy chamber with the glass bottom. Cells 
were allowed to precipitate for 5-7 min and then microscopy images were taken by Zeiss Axiovert 
inverted microscope using 100x objective.  
 
Statistical analysis and correlations 
Statistical analysis was carried out using Graphpad Prism 7.02 and IBM SPSS Statistics 21. One-Way 
ANOVA with Post-Hoc correction (Tukey) was used to test for significant differences between healthy 
controls and HS patients. Also, HS patients with different genotypes were tested to each other and to 
healthy controls. Significant levels of P≤0.05 were considered to reflect significant differences. In figures 
and figure legends significant differences are more specifically noted with * (P≤0.05), † (P≤0.01) or ‡ 
(P≤0.001). Reference values are depicted in gray and were obtained from laboratory references values 
or calculated using mean±(1.96*SD) in healthy controls. Correlations were fitted with linear regression 
and correlations were considered significant when P≤0.05. Genotype-phenotype correlations were only 
carried out for unsplenectomized HS patients (Fig 3). In addition, in all figures splenectomized patients 
are depicted with red dots and were analyzed separately. Fisher’s Exact Test was carried whether the 
phenotypes mild and moderate/severe were equally distributed along the different genotypes (ANK1, 
SLC4A1, SPTB, SPTA1). For Fisher’s Exact Test we categorized the splenectomized patients as 
moderate/severe.  
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